Intersect Ent Inc(XENT) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.

Current Price

$21.04

RSI

39.670

Beta:

1.610038

March 09, 2021
63.7M
-10.8M

-11.104 %
-15.106 %
-159.055 %
-45.444 %

$80,554,000
$109,142,000
$108,472,000
$96,301,000
$78,708,000
$61,593,000
-35.489 %
0.618 %
12.638 %
22.352 %
27.787 %

$-72,735,000
$-54,294,000
$-32,422,000
$-16,363,000
$-25,222,000
$-26,634,000
-25.354 %
-40.284 %
-49.531 %
54.140 %
5.598 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.